Shared on31 Jul 25Fair value Decreased 7.01%
Chemed’s analyst price target has been modestly reduced, as a lower future P/E multiple has more than offset improved revenue growth forecasts, bringing fair value down to $597.50. What's in the News Chemed repurchased 75,000 shares for $42.9 million in Q2 2025, completing a total buyback of 11,053,146 shares (62.45%) under its longstanding program.
Shared on30 Apr 25Fair value Decreased 1.98%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on23 Apr 25Fair value Increased 1.29%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 2.81%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25Fair value Increased 1.48%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.